GCTK vs NXTC vs DXCM vs FATE

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). GlucoTrack, Inc. (GCTK) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate DexCom, Inc. (DXCM) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GlucoTrack, Inc.

(GCTK) is the cheapest at 0. 0x versus DexCom, Inc. at 29. 1x.

Over the past 5 years, DexCom, Inc.

(DXCM) delivered a total return of -32. 1%, compared to -100. 0% for GlucoTrack, Inc. (GCTK). Over 10 years, the gap is even starker: DXCM returned +290. 2% versus GCTK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NextCure, Inc.

(NXTC) is the lower-risk stock at 0. 61β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 255% more volatile than NXTC relative to the S&P 500. On balance sheet safety, NextCure, Inc. (NXTC) carries a lower debt/equity ratio of 12% versus 51% for DexCom, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: GlucoTrack, Inc. grew EPS 258. 6% year-over-year, compared to 17. 7% for NextCure, Inc.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DexCom, Inc.

(DXCM) is the more profitable company, earning 17. 9% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 17. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus -22. 2% for FATE. At the gross margin level — before operating expenses — DXCM leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1525.

5% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NextCure, Inc.

(NXTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NXTC: -95. 7%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GCTK is a small-cap deep-value stock; NXTC is a small-cap quality compounder stock; DXCM is a mid-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.